CN113924311A - 包含修饰的il-2多肽的多肽及其用途 - Google Patents

包含修饰的il-2多肽的多肽及其用途 Download PDF

Info

Publication number
CN113924311A
CN113924311A CN202080018011.6A CN202080018011A CN113924311A CN 113924311 A CN113924311 A CN 113924311A CN 202080018011 A CN202080018011 A CN 202080018011A CN 113924311 A CN113924311 A CN 113924311A
Authority
CN
China
Prior art keywords
leu
polypeptide
antigen
binding domain
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080018011.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·蒂莫尔
B·P·埃克曼
K·M·威利斯
F·J·苏兹迈耶
B·R·贝克兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinxibi Bioscience Co ltd
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of CN113924311A publication Critical patent/CN113924311A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202080018011.6A 2019-01-07 2020-01-06 包含修饰的il-2多肽的多肽及其用途 Pending CN113924311A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
US62/789,075 2019-01-07
PCT/US2020/012296 WO2020146221A1 (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN113924311A true CN113924311A (zh) 2022-01-11

Family

ID=69374426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080018011.6A Pending CN113924311A (zh) 2019-01-07 2020-01-06 包含修饰的il-2多肽的多肽及其用途

Country Status (15)

Country Link
US (1) US20220089667A1 (https=)
EP (1) EP3908596A1 (https=)
JP (2) JP7594161B2 (https=)
KR (1) KR20210113265A (https=)
CN (1) CN113924311A (https=)
AR (1) AR117770A1 (https=)
AU (2) AU2020206672B2 (https=)
BR (1) BR112021012294A2 (https=)
CA (1) CA3125529A1 (https=)
CL (1) CL2021001779A1 (https=)
IL (1) IL284633A (https=)
MX (1) MX2021008147A (https=)
SG (1) SG11202106700WA (https=)
TW (1) TWI874345B (https=)
WO (1) WO2020146221A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
CN114555632A (zh) 2019-08-23 2022-05-27 新索思股份有限公司 Il-15缀合物及其用途
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
KR102313505B1 (ko) * 2020-06-30 2021-10-18 (주)지아이이노베이션 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
TW202216745A (zh) * 2020-07-02 2022-05-01 美商英伊布里克斯公司 包含經修飾ｉｌ－２多肽之多肽及其用途
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
CN116829194A (zh) * 2020-12-09 2023-09-29 亚设生物治疗公司 用于工程化细胞疗法的靶向细胞因子构建体
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
EP4314033A4 (en) * 2021-03-31 2025-04-23 Anwita Biosciences, Inc. FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
WO2023004304A1 (en) * 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-binding polypeptides and uses thereof
EP4395895A1 (en) * 2021-08-30 2024-07-10 Inhibrx, Inc. Nkp46-binding polypeptides and uses thereof
US20240376198A1 (en) * 2021-08-30 2024-11-14 Inhibrx, Inc. NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－２バリアント及びその融合タンパク質
US20250109203A1 (en) * 2022-01-05 2025-04-03 Inhibrx Biosciences, Inc. Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
EP4561632A2 (en) * 2022-07-28 2025-06-04 Proviva Therapeutics (Hong Kong) Limited Il-2 procytokine antibody fusion proteins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086798A2 (en) * 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
CN101426916A (zh) * 2004-03-05 2009-05-06 诺华疫苗和诊断公司 改进的白介素-2突变蛋白
CN102101885A (zh) * 2010-09-01 2011-06-22 宋波 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽
CN105980410A (zh) * 2014-02-06 2016-09-28 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
CN109071623A (zh) * 2016-05-04 2018-12-21 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1678314E (pt) 2003-10-22 2012-11-27 Keck Graduate Inst Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP3795215A1 (en) * 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
WO2017121758A1 (en) * 2016-01-11 2017-07-20 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
IL269000B2 (en) * 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
TWI690538B (zh) * 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086798A2 (en) * 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
CN101426916A (zh) * 2004-03-05 2009-05-06 诺华疫苗和诊断公司 改进的白介素-2突变蛋白
CN102101885A (zh) * 2010-09-01 2011-06-22 宋波 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CN103492411A (zh) * 2011-02-10 2014-01-01 罗切格利卡特公司 突变体白介素-2多肽
CN105980410A (zh) * 2014-02-06 2016-09-28 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
CN109071623A (zh) * 2016-05-04 2018-12-21 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance

Also Published As

Publication number Publication date
JP2022516557A (ja) 2022-02-28
CA3125529A1 (en) 2020-07-16
WO2020146221A1 (en) 2020-07-16
EP3908596A1 (en) 2021-11-17
AU2020206672B2 (en) 2025-10-02
BR112021012294A2 (pt) 2021-09-08
KR20210113265A (ko) 2021-09-15
AU2020206672A1 (en) 2021-07-15
SG11202106700WA (en) 2021-07-29
CL2021001779A1 (es) 2022-03-04
AU2025283608A1 (en) 2026-01-22
AR117770A1 (es) 2021-08-25
US20220089667A1 (en) 2022-03-24
IL284633A (en) 2021-08-31
MX2021008147A (es) 2021-08-11
TWI874345B (zh) 2025-03-01
TW202043259A (zh) 2020-12-01
JP7594161B2 (ja) 2024-12-04
JP2025013911A (ja) 2025-01-28

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
CN116615440A (zh) 包含修饰的il-2多肽的多肽及其用途
JP7462611B2 (ja) Ｏｘ４０結合性ポリペプチド及びその使用
CN114127115A (zh) 结合CLEC12a的多肽及其用途
JP2024526835A (ja) Ｃｄ８結合ポリペプチド及びその使用
KR20240130130A (ko) 감마 델타 t 세포 결합 폴리펩티드 및 그의 용도
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
RU2849624C2 (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
TWI918596B (zh) Ox40結合多肽及其用途
TW202334193A (zh) 靶向γδ T細胞之經修飾IL-2多肽及其用途
CN117980335A (zh) Cd8结合多肽及其用途
HK40050757A (en) Ox40-binding polypeptides and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240926

Address after: California, USA

Applicant after: Yinxibi Bioscience Co.,Ltd.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: INHIBRX L.P.

Country or region before: U.S.A.

TA01 Transfer of patent application right